# EDGAR Filing Document

**Accession Number:** 0001912966
**File Stem:** 0001213900-26-001588
**Filing Date:** 2026-1
**Character Count:** 2634
**Document Hash:** 2457820eb09ef2d407c3aaff53aa3274
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-001588.hdr.sgml**: 20260106

**ACCESSION NUMBER**: 0001213900-26-001588

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260106

**FILED AS OF DATE**: 20260106

**DATE AS OF CHANGE**: 20260106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REGENTIS BIOMATERIALS LTD.
- **CENTRAL INDEX KEY:** 0001912966
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42834
- **FILM NUMBER:** 26509461

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 12 HA'ILAN STREET, NORTHERN INDUSTRIAL
- **STREET 2:** ZONE, P.O. BOX 260
- **CITY:** OR AKIVA
- **PROVINCE COUNTRY:** L3
- **BUSINESS PHONE:** 30600

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 12 HA'ILAN STREET, NORTHERN INDUSTRIAL
- **STREET 2:** ZONE, P.O. BOX 260
- **CITY:** OR AKIVA
- **PROVINCE COUNTRY:** L3

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of January 2026

Commission file number: 001-42834

**<u>REGENTIS BIOMATERIALS LTD.</u>**

(Translation of registrant's name into English)

**60 Medinat Hayehudim Street, 4676652, Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**<u>CONTENTS</u>**

On December 31, 2025, Dr. Eli Hazum resigned as the Chief Executive Officer of Regentis Biomaterials Ltd. (the "Company") effective immediately. Dr. Hazum has indicated his resignation is for personal reasons and not due to any disagreement with the Company.

On the same day, the Company appointed Dr. Ehud Geller, the Chairman of the Company's board of directors, as Chief Executive Officer.

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Regentis Biomaterials Ltd.** | **Regentis Biomaterials Ltd.** |
| Date: January 6, 2026 | By: | /s/ Dr. Ehud Geller |
|  | Name: | Dr. Ehud Geller |
|  | Title: | Chairman and Chief Executive Officer |

---